Analyzing plasma HIV-1 RNA measurements as multiple recurrent events in clinical trials

HIV Clinical Trials

Volumn 7, Issue 3, 2006, Pages 116-124

  Flandre, Philippe ^a   Pinçon, Claire ^b   Aboulker, Jean Pierre ^a   Brun Vézinet, Françoise ^c   Pialoux, Gilles ^d   Raffi, François ^e   Descamps, Diane ^c  

^a INSERM   (France)

^b UNIV LILLE   (France)

^c BICHAT HOSPITAL   (France)

^d HÔPITAL TENON   (France)

^e HÔTEL DIEU   (France)

Author keywords

Clinical trials; Multiple events; Virologic failure

Indexed keywords

INDINAVIR; LAMIVUDINE; VIRUS RNA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; DRUG EFFICACY; DRUG TREATMENT FAILURE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; OPEN STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; REGRESSION ANALYSIS; SURVIVAL; TREATMENT OUTCOME; VIRUS LOAD; VIRUS VIRULENCE;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL MARKERS; CLINICAL TRIALS; HIV INFECTIONS; HIV-1; HUMANS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RNA, VIRAL; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 33748144674     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/FFTX-WQ4H-PFJM-GA8M     Document Type: Article

References (20)

1. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med. 1997;337:725-733.
2. Yéni P, Hammer SM, Hirsh MS, et al. Treatment for adult HIV infection. 2004 Recommendations of the International AIDS Society-USA panel. JAMA. 2004;292:251-265.
3. Gilbert P, DeGruttola V, Hammer SM, Kuritzkes DR. Virologic and regimen termination surrogate endpoints in AIDS clinical trials. JAMA. 2001;285:777-784.
4. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;126:946-954.
5. O'Brien TR, Blattner WA, Waters D, et al. Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. JAMA. 1996;276:105-110
6. Mellors JW, Rinaldo CD Jr, Gupta P, et al. Prognosis in HIV-1 infection predicted by the quantity of virus plasma. Science. 1996;272:1167-1170.
7. Coombs RW, Welles SL, Hooper C, et al. Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. J Infect Dis. 1996;174:704-712.
8. O'Brien WA, Hartigan PM, Martin D, et al. Changes in plasma HIV-1 RNA and CD4+ lymphocytes counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. N Engl J Med. 1996;334:426-431.
9. Marschner IC, Betensky RA, DeGruttola V et al. Clinical trials using HIV-1 RNA based primary endpoints: statistical analysis and potential biases. J Acquir Immune Defic Syndr. 1999;20:220-227.
10. Gilbert PB, Ribaudo HJ, Greenberg L, et al Considerations in choosing a primary endpoint that measures durability of virologic suppression in an antiretroviral trial. AIDS. 2000;14:1-12.
11. Flandre P, Durier C, Descamps D, et al. On the use of magnitude of reduction in HIV-1 RNA in clinical trials: statistical analysis and potential biases. J Acquir Immune Defic Syndr. 2002;30:59-64.
12. Flandre P, Alcais A, Descamps D, et al. Estimating and comparing reduction in HIV-1 RNA in clinical trials using methods for interval censored data. J Acquir Immune Defic Syndr. 2004;35:286-292.
13. Kelly PJ, Lim LL. Survival analysis for recurrent event data: an application to childhood infectious diseases. Stat Med. 2000;19:13-33.
14. Pialoux G, Raffi R, Brun-Vézinet F, et al. A randomized trial of three maintenance regimens following three months of induction therapy with zidovudine, lamivudine and indinavir in naive HIV-1 infected patients. New Engl J Med. 1998;339:1269-1276.
15. Lin DY, Wei LJ. The robust inference for the Cox proportional hazards model. J Am Stat Assoc. 1989;73:351-358.
16. Prentice RL, Williams BJ, Peterson AV. On the regression analysis of multivariate failure time data. Biometrika. 1981;68:373-379.
17. Descamps D, Flandre P, Calvez V, et al. Mechanisms of virologic failure in previously untreated HIV-infected patients from a clinical trial of induction-maintenance therapy. JAMA. 2000;283:205-211.
18. Flandre P, Peytavin G, Meiffredy V, et al. Adherence to antiretroviral therapy and outcomes in HIV-infected patients enrolled in an induction/ maintenance randomized trial. Antiviral Ther. 2002;7:113-121.
19. Hughes JP. Mixed effects models with censored data applications to HIV RNA levels. Biometrics. 1999;55:625-629.
20. Jacqmin-Gadda H, Thiebaut R, Chêne G, Commenges D. Analysis of left-censored longitudinal data with application to viral load in HIV infection. Biostatistics. 2000,1:355-368.